Latest oppositions filed by Octapharma Ag

This table presents recent patent oppositions filed by Octapharma Ag against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3226895Pharmaceutical Product With Increased Stability Comprising ImmunoglobulinsCSL BEHRING AGApr 22, 2021
EP2538975Immunoglobulin Preparation And Storage System For An Immunoglobulin PreparationCSL BEHRING AGJun 18, 2020
EP3116534Compositions Of Human Prothrombin And Activated Factor X For Improving Hemostasis In The Treatment Of Bleeding DisordersBAXALTA GMBHFeb 28, 2020
EP2345425Immunoglobulin G (Igg) Concentrate Depleted Of Anti-A And Anti-B Antibodies And Of Polyreactive IggsLABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESApr 11, 2019
EP2968434C1-Inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor DeficencySHIRE VIROPHARMA INCORPORATEDMar 28, 2018

The following table provides an overview of the latest patents of Octapharma Ag that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3626737Nov 29, 2023A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant Fviii2
EP2707387Dec 25, 2019A Method Of Increasing The Productivity Of Eucaryotic Cells In The Production Of Recombinant Fviii1
EP2640413Jun 12, 2019A Process For Reduction And/Or Removal Of Fxi And Fxia From Solutions Containing Said Coagulation Factors1
EP2670429Apr 4, 2018Method For Inactivation/Removal Of Coagulation Factors By Precipitation2
EP2825555Jul 12, 2017Improved Process For Production Of Fibrinogen And Fibrinogen Produced Thereby2